AP026, a FGF21 (fibroblast growth factor 21)/ GLP-1 (glucagon-like peptide-1) bifunctional protein, is currently undergoing phase 1 clinical development for the treatment of NASH and type 2 diabetes mellitus (T2DM). This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.